Stock data
Matinas Biopharma Holdings, Inc. (MTNB)
Matinas Biopharma Holdings, Inc. (MTNB) reported net income of -US$10.35M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$6.96M | -US$10.35M | — |
| 2024 | — | — | -US$24.59M | -US$24.25M | — |
| 2023 | US$1.10M | — | -US$23.77M | -US$22.94M | — |
| 2022 | US$3.19M | — | -US$24.59M | -US$21.00M | — |
| 2021 | US$0.03M | — | -US$24.73M | -US$23.28M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$1.33M | — |
| 2026-03-31 | — | -US$1.92M | — |
| 2025-12-31 | — | -US$1.91M | — |
| 2025-09-30 | — | -US$1.53M | — |
| 2025-06-30 | — | -US$5.25M | — |
| 2025-03-31 | — | -US$1.66M | — |
| 2024-12-31 | — | -US$8.43M | — |
| 2024-09-30 | — | -US$4.28M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.